SI-BONE (NASDAQ:SIBN) posted its quarterly earnings results on Sunday. The company reported ($0.37) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.03, MarketWatch Earnings reports. SI-BONE had a negative return on equity of 45.03% and a negative net margin of 61.67%.
SIBN stock traded down $2.88 during midday trading on Tuesday, reaching $33.08. 25,822 shares of the stock were exchanged, compared to its average volume of 287,842. The stock has a market capitalization of $1.09 billion, a PE ratio of -20.62 and a beta of 1.41. SI-BONE has a 52 week low of $14.37 and a 52 week high of $36.78. The company has a debt-to-equity ratio of 0.39, a current ratio of 12.65 and a quick ratio of 12.22. The company has a fifty day moving average price of $33.10 and a 200 day moving average price of $28.78.
A number of research analysts have weighed in on SIBN shares. Zacks Investment Research downgraded SI-BONE from a “hold” rating to a “sell” rating in a research note on Friday, March 12th. Canaccord Genuity lifted their target price on SI-BONE from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday. Truist lifted their target price on SI-BONE from $35.00 to $43.00 in a research note on Tuesday. Morgan Stanley lifted their target price on SI-BONE from $38.00 to $41.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Needham & Company LLC lifted their target price on SI-BONE from $34.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. SI-BONE has a consensus rating of “Buy” and a consensus price target of $36.63.
SI-BONE Company Profile
SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Featured Article: Futures Contract
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.